Evidence map›Paper›PMID 42193896›Full record

ArticleCells2026

Comparative Characterization of Leukocyte-Rich Platelet-Rich Plasma (L-PRP) and Injectable Platelet-Rich Fibrin (i-PRF): A Laboratory Study.

André Vinicius Saueressig Kruel, Mariângela Ferreira, Daiane Agostini, Cristiano Valter Diesel, Marcelo Queiroz, Carlos Roberto Galia, Guilherme Liberato da Silva, Stephany Huber, Fernanda Majolo

Abstract readComparative Study
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

André Vinicius Saueressig KruelClínica PROREGEN, Bento Gonçalves 95700-066, RS, Brazil.ORCID 0000-0002-7415-3953
Mariângela FerreiraClínica PROREGEN, Bento Gonçalves 95700-066, RS, Brazil.
Daiane AgostiniClínica PROREGEN, Bento Gonçalves 95700-066, RS, Brazil.ORCID 0009-0003-8810-5383
Cristiano Valter DieselHospital Moinhos de Vento, Porto Alegre 90560-032, RS, Brazil.
Marcelo QueirozHospital Israelita Albert Einstein, São Paulo 05651-901, SP, Brazil.
Carlos Roberto GaliaHospital de Clínicas de Porto Alegre, Porto Alegre 90410-000, RS, Brazil.
Guilherme Liberato da SilvaPrograma de Pós-Graduação em Ciências Médicas (PPGCM), Universidade do Vale do Taquari (Univates), Lajeado 95914-014, RS, Brazil.ORCID 0000-0001-6619-6622
Stephany HuberOrthoregen Medicina, Ensino e Pesquisa, Indaiatuba 13334-170, SP, Brazil.ORCID 0000-0003-3322-0598
Fernanda MajoloPrograma de Pós-Graduação em Biotecnologia (PPGBiotec), Universidade do Vale do Taquari (Univates), Lajeado 95914-014, RS, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOrthobiologics such as Platelet-Rich Plasma (PRP) and Injectable Platelet-Rich Fibrin (i-PRF) have emerged as promising tools in regenerative medicine. However, the lack of methodological standardization and the still limited comparative characterization between these products represent significant barriers to their optimized clinical application. This comparative laboratory study aimed to characterize and differentiate PRP and i-PRF, focusing on their cellular composition, obtained volume, and total Platelet-Derived Growth Factor (PDGF-BB) content. MATERIALS AND

methodsThis study was conducted with 34 individuals meeting standard blood donation criteria. Peripheral blood samples were collected from all participants. PRP was obtained using a modified double-spin centrifugation protocol, whereas i-PRF was prepared using a modified low-speed centrifugation technique. Cellularity (platelet and leukocyte counts), final produced volume, and total PDGF-BB content were assessed using complete blood count analysis and an enzyme-linked immunosorbent assay (ELISA), respectively. Statistical analysis was performed using Linear Mixed Models (LMMs).

resultsBoth protocols resulted in significant increases in platelet and leukocyte concentrations compared to baseline values. PRP showed significantly higher platelet and leukocyte concentrations compared with i-PRF, as well as markedly higher PDGF-BB levels. In contrast, i-PRF yielded a substantially greater final volume and enabled a higher absolute delivery of total leukocytes, whereas PRP delivered a greater absolute number of platelets. In exploratory analyses, female sex, the presence of comorbidities, and increased abdominal circumference were associated with variations in product volume and cellular composition. DISCUSSION: These findings indicate that PRP and i-PRF exhibit distinct biological profiles in terms of cellularity, volume, and total PDGF-BB content. Whether these laboratory differences translate into distinct clinical outcomes remains unknown. The results should therefore be viewed as hypothesis-generating: they suggest that PRP and i-PRF may not be interchangeable, and that future randomized clinical trials are needed to define product-specific indications based on the target tissue and desired biological mechanism.

Indexed as

LeukocytesPlatelet-Rich FibrinPlatelet-Rich PlasmaAdultBecaplerminBlood PlateletsFemaleHumansInjectionsMaleMiddle AgedProto-Oncogene Proteins c-sisBecaplerminProto-Oncogene Proteins c-sisblood plateletsgrowth factorsplatelet-rich fibrinplatelet-rich plasmaregenerative medicine

Identifiers

PMID42193896
PMCPMC13204340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.